Wednesday, Novartis AG (NYSE:NVS) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints. V-MONO is part of the 60,000-patient ...

LEQVIO (inclisiran) is a first-of-its-kind therapy developed by Novartis based on small interfering RNA (siRNA) technology. It targets the mRNA of PCSK9 (proprotein convertase subtilisin/kexin type 9) ...

Credit: Novartis. The expanded approval now includes patients with comorbidities who have not yet had a first cardiovascular event. The Food and Drug Administration (FDA) has updated the indication ...

Novartis has shared positive top-line results from a late-stage study evaluating Leqvio (inclisiran) as a monotherapy for patients who are at risk of developing atherosclerotic cardiovascular disease ...

Credit: Novartis. The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD. The Food and ...

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio ® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy ...

Novartis NVS announced new long-term data on the cholesterol-lowering drug Leqvio at the European Society of Cardiology (“ESC”) Congress 2023 in Amsterdam. Leqvio is the first and only small ...

FRISCO, Texas--(BUSINESS WIRE)--Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected as a limited distribution partner ...

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1 Leqvio provides effective and sustained LDL-C ...

The drug, inclisiran, is part of a relatively new class of genetic medicines that work by stopping production of a problem protein. In the case of the Novartis drug, which will be marketed under the ...